Dr. Kelley on the Development of Biomarkers for HCC

R. Kate Kelley, MD
Published: Wednesday, Jun 07, 2017



R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).

The potential of many therapies in development depends on identifying the patient groups most likely to benefit, explains Kelley. This will require a better understanding of the biology of HCC.

According to Kelley, the potential of new therapies will drive a wave of research to further define the relevant subgroups.
 


R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).

The potential of many therapies in development depends on identifying the patient groups most likely to benefit, explains Kelley. This will require a better understanding of the biology of HCC.

According to Kelley, the potential of new therapies will drive a wave of research to further define the relevant subgroups.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x